SCHEMBL566334

SCHEMBL566334

Ic1cccc2ncccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.58
KDM4E B2RXH2 2/20 0.58
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.47
LMNA P02545 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HTT P42858 3/20 0.45
HSP90AA1 P07900 2/20 0.45
HIF1A Q16665 2/20 0.45
HSP90AB1 P08238 1/20 0.45
BLM P54132 1/20 0.45
ALDH1A1 P00352 3/20 0.44
NCF1 P14598 1/20 0.43
HDAC6 Q9UBN7 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
PABPC1 P11940 2/20 0.41
EIF4H Q15056 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949255 0.84 NCF1 (0.56) MAPTKDM4ECYP3A4MEN1KMT2A
SCHEMBL198641 0.76 MAPT (0.64) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL11526779 0.76 MAPT (0.62) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL217044 0.75 MAPT (1.00) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL8384663 0.74 MAPT (0.61) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL1282250 0.74 MAPT (0.54) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL30123180 0.74 MAPT (0.54) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL3967767 0.74 MAPT (0.54) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL18848333 0.74 KDM4E (0.48) MAPTKDM4EPOLBCYP3A4LMNA
SCHEMBL18434615 0.74 MAPT (0.54) MAPTKDM4EPOLBCYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496151-A Method for preparing fluorenone derivative by using Catellani strategy 长沙医学院 2023-07-28 CN claimed
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2026-03-03 US disclosed
WO-2025129168-A1 TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-06-19 WO disclosed
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-05-29 US disclosed
CN-119219602-A 4-Lauryl-beta-lactam derivative and preparation method thereof 苏州大学 2024-12-31 CN disclosed
CN-119143673-A 5-Aryl benzophenanthridine-6 (5H) -ketone C-N axis chiral compound and preparation method and application thereof 浙江大学杭州国际科创中心 2024-12-17 CN disclosed
CN-118955428-A Benzothiazinone vinylidene indene series compound with dibenzothiazepine octacycle system structure and preparation method thereof 浙大城市学院 2024-11-15 CN disclosed
CN-116496151-B Method for preparing fluorenone derivative by utilizing CATELLANI strategy 长沙医学院 2024-08-23 CN disclosed
US-20230371357-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-16 US disclosed
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed
US-6124460-A Isoquinuclidine derivatives, method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds KOTOBUKI PHARMACEUTICAL CO. LTD. (JP) 2000-09-26 US disclosed
US-5776939-A PIPERAZINE DERIVATIVES ELI LILLY AND COMPANY (US) 1998-07-07 US disclosed
WO-1998022112-A1 DRUG RESISTANCE AND MULTIDRUG RESISTANCE MODULATORS ELI LILLY AND COMPANY (US) 1998-05-28 WO disclosed
EP-0844244-A1 Drug resistance and multidrug resistance modulators ELI LILLY AND COMPANY (US) 1998-05-27 EP disclosed
US-4052509-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-10-04 US disclosed
US-4042699-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-08-16 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230371357-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE L1CAM, CHRM1, FOXM1 MAPT 775/4885KDM4E 3285/4885POLB 2882/4885
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 MAPT 1855/4885KDM4E 3624/4885POLB 3431/4885
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 MAPT 2127/4885KDM4E 3909/4885POLB 3691/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 MAPT 1802/4885KDM4E 3715/4885POLB 3455/4885
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 MAPT 458/4885KDM4E 3057/4885POLB 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.